Skip to main content

Advertisement

Table 1 Demographics and baseline characteristics of patients with and without enthesitis at baseline

From: Secukinumab efficacy on resolution of enthesitis in psoriatic arthritis: pooled analysis of two phase 3 studies

CharacteristicWith enthesitis at baselineWithout enthesitis at baseline
SecukinumabPlacebo (N = 163)SecukinumabPlacebo (N = 72)
300 mg (N = 144)150 mg (N = 159)300 mg (N = 95)150 mg (N = 79)
Age (years), mean (SD)48.3 (12.5)48.0 (11.8)48.9 (13.3)46.5 (13.7)48.7 (12.8)50.4 (11.9)
Female, %555369444833
Weight (kg), mean (SD)88.1 (21.0)90.8 (19.4)82.9 (18.9)83.8 (15.1)84.1 (17.8)85.3 (16.4)
Caucasian, %959397969296
TNFi-naïve, %686364677272
Time since first diagnosis of PsA (years), mean (SD)7.7 (8.7)7.4 (8.8)6.8 (7.0)8.2 (8.4)6.7 (7.6)7.1 (8.0)
Number of enthesitis sites, mean (SD)3.0 (1.7)3.2 (1.7)3.0 (1.6)000
Tender joint total score (78 joints), mean (SD)*23.5 (15.6)27.0 (19.8)26.3 (18.4)14.6 (9.6)16.9 (13.6)14.1 (11.2)
Swollen joint total score (76 joints), mean (SD)*10.3 (6.9)12.2 (10.1)12.1 (10.3)9.3 (7.4)10.0 (8.1)8.6 (7.1)
DAS28-CRP, mean (SD)4.8 (1.0)4.9 (1.1)4.9 (1.1)4.3 (1.0)4.4 (1.1)4.3 (0.9)
HAQ-DI, mean (SD)1.3 (0.7)1.2 (0.6)1.3 (0.6)1.0 (0.6)1.2 (0.6)1.1 (0.7)
Patient global assessment, mean (SD)N = 142, 62.6 (18.7)N = 156, 61.6 (21.6)N = 161, 62.2 (20.1)N = 95, 56.6 (21.5)N = 79, 59.1 (19.9)N = 72, 53.1 (19.9)
Physician global assessment, mean (SD)N = 143, 54.4 (18.3)N = 158, 57.0 (16.4)N = 163, 57.1 (15.7)N = 94, 51.0 (16.8)N = 79, 53.6 (17.0)N = 72, 49.9 (19.4)
  1. DAS28-CRP 28-Joint Disease Activity Score count using C-reactive protein, HAQ-DI Health Assessment Questionnaire Disability Index, PsA psoriatic arthritis, SD standard deviation, TNF tumor necrosis factor
  2. *In case of joints for which the data was not available, the observed count of the joints was scaled up proportionately